WEST virginia legislature
2018 regular session
Introduced
House Bill 4336
By Delegates Ellington, Summers, Rohrbach, Householder, Atkinson, Criss, Hollen, Hill, Rowan, Dean and Cooper
[Introduced January 26,
2018; Referred
to the Committee on Prevention and Treatment of Substance Abuse then the
Judiciary.]
A BILL to amend and reenact §60A-2-204, §60A-2-206, §60A-2-210 and §60A-2-212 of the Code of West Virginia, 1931, as amended, all relating to updating the schedule of controlled substances.
Be it enacted by the Legislature of West Virginia:
ARTICLE 2. STANDARDS AND SCHEDULES.
§60A-2-204. Schedule I.
(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation.
(b) Opiates. Unless
specifically excepted or unless listed in another schedule, any of the
following opiates, including their isomers, esters, ethers, salts and salts of
isomers, esters and ethers, whenever the existence of such isomers, esters,
ethers and salts is possible within the specific chemical designation (for purposes
of subdivision (34) of this subsection only, the term isomer includes the
optical and geometric isomers):
(1) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl) -4-piperidinyl]--phenylacetamide);
(2) Acetylmethadol;
(3) Allylprodine;
(4) Alphacetylmethadol
(except levoalphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);
(5) Alphameprodine;
(6) Alphamethadol;
(7)
Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl]
propionanilide; 1-(1-methyl-2-phenylethyl)-4-(– propanilido) piperidine);
(8) Alpha-methylthiofentanyl
(N-[1-methyl-2-(2-thienyl) ethyl- 4-piperidinyl]--phenylpropanamide);
(9)
Benzethidine;
(10)
Betacetylmethadol;
(11) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl) -4- piperidinyl]-N-phenylpropanamide);
(12)
Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2- hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide);
(13)
Betameprodine;
(14)
Betamethadol;
(15)
Betaprodine;
(16)
Clonitazene;
(17)
Dextromoramide;
(18)
Diampromide;
(19)
Diethylthiambutene;
(20)
Difenoxin;
(21)
Dimenoxadol;
(22)
Dimepheptanol;
(23)
Dimethylthiambutene;
(24)
Dioxaphetyl butyrate;
(25)
Dipipanone;
(26)
Ethylmethylthiambutene;
(27)
Etonitazene;
(28)
Etoxeridine;
(29)
Furethidine;
(30)
Hydroxypethidine;
(31)
Ketobemidone;
(32)
Levomoramide;
(33)
Levophenacylmorphan;
(34) 3-Methylfentanyl
(N-[3-methyl-1-(2-phenylethyl)-4- piperidyl]-N-phenylpropanamide);
(35) 3-methylthiofentanyl
(N-[3-methyl-1-(2-thienyl) ethyl-4- piperidinyl]--phenylpropanamide);
(36)
Morpheridine;
(37) MPPP
(1-methyl-4-phenyl-4-propionoxypiperidine);
(38)
Noracymethadol;
(39)
Norlevorphanol;
(40)
Normethadone;
(41)
Norpipanone;
(42) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- phenethyl)-4-piperidinyl]
propanamide);
(43)
PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(44)
Phenadoxone;
(45) Phenampromide;
(46)
Phenomorphan;
(47)
Phenoperidine;
(48)
Piritramide;
(49)
Proheptazine;
(50)
Properidine;
(51)
Propiram;
(52)
Racemoramide;
(53)
Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidinyl]-propanamide);
(54)
Tilidine;
(55)
Trimeperidine.
(c) Opium derivatives: -- Unless
specifically excepted or unless listed in another schedule, any of the
following opium immediate derivatives, its salts, isomers and salts of isomers
whenever the existence of such salts, isomers and salts of isomers is possible
within the specific chemical designation:
(1)
Acetorphine;
(2)
Acetyldihydrocodeine;
(3)
Benzylmorphine;
(4) Codeine
methylbromide;
(5)
Codeine-N-Oxide;
(6)
Cyprenorphine;
(7)
Desomorphine;
(8)
Dihydromorphine;
(9)
Drotebanol;
(10)
Etorphine (except HCl Salt);
(11) Heroin;
(12)
Hydromorphinol;
(13)
Methyldesorphine;
(14)
Methyldihydromorphine;
(15)
Morphine methylbromide;
(16)
Morphine methylsulfonate;
(17)
Morphine-N-Oxide;
(18)
Myrophine;
(19)
Nicocodeine;
(20)
Nicomorphine;
(21) Normorphine;
(22)
Pholcodine;
(23)
Thebacon.
(d) Hallucinogenic substances. -- Unless
specifically excepted or unless listed in another schedule, any material,
compound, mixture or preparation, which contains any quantity of the following
hallucinogenic substances, or which contains any of its salts, isomers and
salts of isomers, whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation (for purposes of
this subsection only, the term "isomer" includes the optical,
position and geometric isomers):
(1)
Alpha-ethyltryptamine; some trade or other names: etryptamine; Monase;
alpha-ethy-1H-indole-3-ethanamine; 3-(2- aminobutyl) indole; alpha-ET; and AET;
(2)
4-bromo-2, 5-dimethoxy-amphetamine; some trade or other names:
4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo- 2,5-DMA;
(3)
4-Bromo-2,5-dimethoxyphenethylamine; some trade or other names:
2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha- desmethyl DOB; 2C-B,
Nexus;
(4)(A)
N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine. The substance has the
acronym 25B-NBOMe.
(B)
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe)
(C)
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe)
(5)
2,5-dimethoxyamphetamine; some trade or other names:
2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA;
(6)
2,5-dimethoxy-4-ethylamphet-amine; some trade or other names: DOET;
(7)
2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
(8) 4-methoxyamphetamine;
some trade or other names: 4-methoxy-alpha-methylphenethylamine;
paramethoxyamphetamine; PMA;
(9)
5-methoxy-3, 4-methylenedioxy-amphetamine;
(10)
4-methyl-2,5-dimethoxy-amphetamine; some trade and other names:
4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP";
(11)
3,4-methylenedioxy amphetamine;
(12)
3,4-methylenedioxymethamphetamine (MDMA);
(13)
3,4-methylenedioxy-N-ethylamphetamine (also known as – ethyl-alpha-methyl-3,4
(methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
(14)
N-hydroxy-3,4-methylenedioxyamphetamine (also known as –
hydroxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and – hydroxy MDA);
(15)
3,4,5-trimethoxy amphetamine;
(15) (16)
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
(17)
Alpha-methyltryptamine (other name: AMT);
(18)
Bufotenine; some trade and other names:
3-(beta-Dimethylaminoethyl)-5-hydroxyindole;3-(2-dimethylaminoethyl)
-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N- dimethyltryptamine; mappine;
(19)
Diethyltryptamine; sometrade and other names: N, N-Diethyltryptamine; DET;
(20)
Dimethyltryptamine; some trade or other names: DMT;
(21)
5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
(22)
Ibogaine; some trade and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12,
13-octahydro-2-methoxy-6, 9-methano-5H- pyrido [1', 2': 1, 2] azepino [5,4-b]
indole; Tabernanthe iboga;
(23)
Lysergic acid diethylamide;
(24)
Marihuana;
(25)
Mescaline;
(26)
Parahexyl-7374; some trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9,
10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;
(27) Peyote;
meaning all parts of the plant presently classified botanically as Lophophora
williamsii Lemaire, whether growing or not, the seeds thereof, any extract from
any part of such plant, and every compound, manufacture, salts, immediate
derivative, mixture or preparation of such plant, its seeds or extracts;
(28)
N-ethyl-3-piperidyl benzilate;
(29)
N-methyl-3-piperidyl benzilate;
(30) Psilocybin;
(31)
Psilocyn;
(32)
Tetrahydrocannabinols; synthetic equivalents of the substances contained in the
plant, or in the resinous extractives of Cannabis, sp. and/or synthetic
substances, immediate derivatives and their isomers with similar chemical structure
and pharmacological activity such as the following:
delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;
delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;
delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;
(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.)
(33)
Ethylamine analog of phencyclidine; some trade or other names:
N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine,
N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
(34)
Pyrrolidine analog of phencyclidine; some trade or other names:
1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
(35)
Thiophene analog of phencyclidine; some trade or other names:
1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine;
TPCP, TCP;
(36)
1[1-(2-thienyl)cyclohexyl]pyrroldine; some other names: TCPy.
(37)
4-methylmethcathinone (Mephedrone);
(38)
3,4-methylenedioxypyrovalerone (MDPV);
(39)
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(40)
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)
(41)
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)
(42)
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)
(43)
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)
(44)
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)
(45)
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
(46)
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)
(47)
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)
(48)
3,4-Methylenedioxy-N-methylcathinone (Methylone)
(49)
2,5-dimethoxy-4-(n)-propyltghiophenethylamine (2C-T-7, itsoptical isomers,
salts and salts of isomers
(50)
5-methoxy-N,N-dimethyltryptamine some trade or other names:
5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT)
(51)
Alpha-methyltryptamine (other name: AMT)
(52)
5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT)
(53)
Synthetic Cannabinoids as follows:
(A)
2-[(1R,3S)-3-hydroxycyclohexyl]-5- (2-methyloctan-2-yl)phenol) {also known as
CP 47,497 and homologues};
(B)
rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol {also known
as CP 47,497-C8 homolog};
(C) [(6aR)-9-(hydroxymethyl)-6,
6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a-tetrahydrobenzo[c]chromen-1-ol)]
{also known as HU-210};
(D)
(dexanabinol);
(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzol[c]chromen-1-ol) {also known as HU-211};
(E)
1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-018};
(F)
1-Butyl-3-(1-naphthoyl)indole {also known as JWH-073};
(G)
(2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-methanone {also known as
JWH-015};
(H)
(1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-019};
(I)
[1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone {also
known as JWH-200};
(J)
1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone {also known as
JWH-250};
(K)
2-((1S,2S,5S)-5-hydroxy-2- (3-hydroxtpropyl)cyclohexyl) -5-(2-methyloctan-2-yl)phenol
{also known as CP 55,940};
(L)
(4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as
JWH-
122};
(M)
(4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as
JWH-
398;
(N)
(4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone {also known as RCS-4};
(O)
1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone {also
known as RCS-8};
(P)
1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
(Q)
1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
(R)
1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
(54)
Synthetic cannabinoids: or any material, compound, mixture or preparation
which contains any quantity of the following substances, including their
analogues, congeners, homologues, isomers, salts and salts of analogues,
congeners, homologues and isomers, as follows:
(A) CP
47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
YL)phenol);
(B) HU-210,
[(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
10A-tetrahydrobenzo[C] chromen-1-OL)];
(C) HU-211,
(dexanabinol,
(6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2-YL)-6A,7,10,10atetrahydrobenzo[
C]chromen-1-OL);
(D) JWH-018,
1-pentyl-3-(1-naphthoyl)indole;
(E) JWH-019,
1-hexyl-3-(1-naphthoyl)indole;
(F) JWH-073,
1-butyl-3-(1-naphthoyl)indole;
(G) JWH-200,
(1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
(H) JWH-250,
1-pentyl-3-(2-methoxyphenylacetyl)indole.]
Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-ADB);
Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (FUB-AMB);
N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA);
Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA);
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-FUBINACA);
(55) Synthetic cannabinoids including any material,
compound, mixture or preparation that is not listed as a controlled substance
in Schedule I through V, is not a federal Food and Drug Administration approved
drug or used within legitimate and approved medical research and which contains
any quantity of the following substances, their salts, isomers, whether optical
positional or geometric, analogues, homologues and salts of isomers, analogues
and homologues, unless specifically exempted, whenever the existence of these
salts, isomers, analogues, homologues and salts of isomers, analogues and
homologues if possible within the specific chemical designation:
(A)
Tetrahydrocannabinols: meaning tetrahydrocannabinols which are naturally
contained in a plant of the genus cannabis as well as synthetic equivalents of
the substances contained in the plant or in the resinous extractives of
cannabis or synthetic substances, derivatives and their isomers with analogous
chemical structure and or pharmacological activity such as the following:
(i) DELTA-1
CIS OR trans tetrahydrocannabinol and their Optical isomers.
(ii) DELTA-6
CIS OR trans tetrahydrocannabinol and their optical isomers.
(iii)
DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
(56)
Synthetic Phenethylamines (including their optical, positional, and
geometric isomers, salts and salts of isomers, whenever the existence of such
salts, isomers, and salts of isomers):
(A)
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe/
2C-I-NBOMe);
(B)
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(25C-NBOMe/2C-C-NBOMe);
(C)
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/
2C-B-NBOMe);
(57)
Synthetic Opioids (icluding their isomers, esters, ethers, salts and salts of
isomers, esters and ethers):
(A)
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
(B) furanyl
fentanyl;
(C)
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as
U-47700);
(D)
N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as
N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);
(E)
N-[1-[2-hydroxy-2-(thiophen-2-yl)ethylpiperidin-4-yl]-N-phenylpropionamide,
also known as
N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide,
(beta-hydroxythiofentanyl).
N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl)
N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl)
N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl)
2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide (also known as
U-48800)
Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as U-49900)
Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide (also known as
U-51754)
(58) Opioid
Receptor Agonist (including its isomers, esters, ethers, salts, and salts of
isomers, esters and ethers):
(A) AH-7921
(3,4-dichloro-N- (1dimethylamino)cyclohexylmethyl]benzamide).
(B)
Naphthoylindoles or any compound containing a 3-(-1- Napthoyl) indole structure
with substitution at the nitrogen atom of the indole ring whether or not
further substituted in the indole ring to any extent and whether or not
substituted in the naphthyl ring to any extent. This shall include the
following:
(i) JWH 015;
(ii) JWH
018;
(iii) JWH
019;
(iv) JWH
073;
(v) JWH 081;
(vi) JWH
122;
(vii) JWH
200;
(viii) JWH
210;
(ix) JWH
398;
(x) AM 2201;
(xi) WIN
55,212.
(59)
Naphylmethylindoles or any compound containing a 1hindol-3-yl-(1-naphthyl)
methane structure with a substition at the nitrogen atom of the indole ring
whether or not further substituted in the indole ring to any extent and whether
or not substituted in the naphthyl ring to any extent. This shall include, but
not be limited to, JWH 175 and JWH 184.
(60)
Naphthoylpyrroles or any compound containing a 3-(1- Naphthoyl) pyrrole
structure with substitution at the nitrogen atom of the pyrrole ring whether or
not further substituted in the pyrrole ring to any extent and whether or not
substituted in the naphthyl ring to any extent. This shall include, but not be
limited to, JWH 147 and JWH 307.
(61) Naphthylmethylindenes
or any compound containing a Naphthylideneindene structure with substitution at
the 3- Position of the indene ring whether or not further substituted in the
indene ring to any extent and whether or not substituted in the naphthyl ring to
any extent. This shall include, but not be limited to, JWH 176.
(62)
Phenylacetylindoles or any compound containing a 3- Phenylacetylindole
structure with substitution at the nitrogen atom of the indole ring whether or
not further substituted in the indole ring to any extent and whether or not
substituted in the phenyl ring to any extent. This shall include the following:
(A) RCS-8,
SR-18 OR BTM-8;
(B) JWH 250;
(C) JWH 203;
(D) JWH 251;
(E) JWH 302.
(63)
Cyclohexylphenols or any compound containing a 2-(3- hydroxycyclohexyl) phenol
structure with a substitution at the 5-position of the phenolic ring whether or
not substituted in the cyclohexyl ring to any extent. This shall include the
following:
(A) CP
47,497 and its homologues and analogs;
(B)
Cannabicyclohexanol;
(C) CP
55,940.
(64)
Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with
substitution at the nitrogren atom of the indole ring whether or not further
substituted in the indole ring to any extent and whether or not substituted in
the phenyl ring to any extent. This shall include the following:
(A) AM 694;
(B)
Pravadoline WIN 48,098;
(C) RCS 4;
(D) AM 679.
(62)
[2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1,
4-benzoxazin-6-YL]-1-napthalenymethanone. This shall include WIN 55,212-2.
(65)
Dibenzopyrans or any compound containing a 11-hydroxydelta
8-tetrahydrocannabinol structure with substitution on the 3-pentyl group. This
shall include HU-210, HU-211, JWH 051 and JWH 133.
(66)
Adamantoylindoles or any compound containing a 3-(-1- Adamantoyl) indole
structure with substitution at the nitrogen atom of the indole ring whether or
not further substituted in the adamantoyl ring system to any extent. This shall
include AM1248.
(67)
Tetramethylcyclopropylindoles or any compound containing A
3-tetramethylcyclopropylindole structure with substitution at the nitrogen atom
of the indole ring whether or not further substituted in the indole ring to any
extent and whether or not substituted in the tetramethylcyclopropyl ring to any
extent. This shall include UR-144 and XLR-11.
(68)
N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48.
(69) Any
other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist
as demonstrated by binding studies and functional assays that is not listed in
Schedules II, III, IV and V, not federal Food and Drug Administration approved
drug or used within legitimate, approved medical research. Since nomenclature
of these substances is not internationally standardized, any immediate
precursor or immediate derivative of these substances shall be covered.
(70)
Tryptamines:
(A) 5-
methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT)
(B)
4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT)
(C)
4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT)
(D)
4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)
(E)
4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT)
(F)
5-methoxy-α-methyltryptamine (5-MeO-AMT)
(G)
4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT)
(H)
4-hydroxy Diethyltryptamine (4-HO-DET)
(I) 5-
methoxy- N,N- diallyltryptamine (5-MeO-DALT)
(J)
4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT)
(K)
4-hydroxy Diethyltryptamine (4-HO-DET)
(e) Depressants. -- Unless specifically
excepted or unless listed in another schedule, any material, compound, mixture,
or preparation which contains any quantity of the following substances having a
depressant effect on the central nervous system, including its salts, isomers
and salts of isomers whenever the existence of such salts, isomers and salts of
isomers is possible within the specific chemical designation:
(1)
Mecloqualone;
(2)
Methaqualone.
(f) Stimulants. -- Unless specifically
excepted or unless listed in another schedule, any material, compound, mixture,
or preparation which contains any quantity of the following substances having a
stimulant effect on the central nervous system, including its salts, isomers
and salts of isomers:
(1)
Aminorex; some other names: aminoxaphen; 2-amino-5- phenyl-2-oxazoline; or
4,5-dihydro-5-phenyl-2-oxazolamine;
(2)
Cathinone; some trade or other names: 2-amino-1-phenyl-1- propanone,
alpha-aminopropiophenone, 2-aminopropiophenone and norephedrone;
(3)
Fenethylline;
(4)
Methcathinone, its immediate precursors and immediate derivatives, its salts,
optical isomers and salts of optical isomers; some other names:
(2-(methylamino)-propiophenone; alpha-
(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1- one; alpha---methylaminopropiophenone; monomethylpropion; 3,4-methylenedioxypyrovalerone and/or mephedrone;3,4-methylenedioxypyrovalerone (MPVD); ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL- 463 and UR1432;
(5) (+-)
cis-4-methylaminorex; ((+-)cis-4,5-dihydro-4-methyl- 5-phenyl-2-oxazolamine);
(6)
N-ethylamphetamine;
(7)
N,N-dimethylamphetemine; also known as N,N-alpha- trimethyl-benzeneethanamine;
N,N-alpha-trimethylphenethylamine.
(8)
Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts
and salts of isomers.
(9)
Substituted amphetamines:
(A)
2-Fluoroamphetamine
(B)
3-Fluoroamphetamine
(C)
4-Fluoroamphetamine
(D)
2-chloroamphetamine
(E)
3-chloroamphetamine
(F)
4-chloroamphetamine
(G)
2-Fluoromethamphetamine
(H)
3-Fluoromethamphetamine
(I)
4-Fluoromethamphetamine
(J)
4-chloromethamphetamine
(g) Temporary listing of substances subject to emergency scheduling. Any material, compound, mixture or preparation which contains any quantity of the following substances:
(1)
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical
isomers, salts, and salts of isomers.
(2)
N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its
optical isomers, salts and salts of isomers.
(3)
N-benzylpiperazine, also known as BZP.
(4)
Cyclopentyl fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
(5)
4-fluorobutyryl fentanyl
(N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]-butyramide);
(6)
Isobutyryl fentanyl
(2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-propanamide);
(7)
Methoxyacetyl fentanyl
(2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-acetamide);
(8)
3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-phenylbutyramide);
(9)
4-methoxybutyryl fentanyl
(N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);
(10)
Ocfentanil
(N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]-acetamide);
(11)
Tetrahydrofuran fentanyl
(N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
(12)
Valeryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide).
(h) The following controlled substances are included in Schedule I:
(1)
Synthetic Cathinones or any compound, except bupropion or compounds listed
under a different schedule, or compounds used within legitimate and approved
medical research, structurally derived from 2- Aminopropan-1-one by
substitution at the 1-position with Monocyclic or fused polycyclic ring
systems, whether or not the compound is further modified in any of the
following ways:
(A) By
substitution in the ring system to any extent with Alkyl, alkylenedioxy,
alkoxy, haloalkyl, hydroxyl or halide Substituents whether or not further
substituted in the ring system by one or more other univalent substituents.
(B) By
substitution at the 3-position with an acyclic alkyl substituent.
(C) By
substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl
groups.
(D) By
inclusion of the 2-amino nitrogen atom in a cyclic structure.
(2) Any other synthetic chemical compound that is a
Cannabinoid receptor type 1 agonist as demonstrated by binding studies and
functional assays that is not listed in Schedules II, III, IV and V, not
federal Food and Drug Administration approved drug or used within legitimate,
approved medical research.
§60A-2-206. Schedule II.
(a) Schedule II consists of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section.
(b) Substances, vegetable origin or chemical synthesis. -- Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
(1) Opium and opiate, and any salt, compound, derivative
or preparation of opium or opiate excluding apomorphine, thebaine-derived
butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone, and
their respective salts, but including the following:
(A) Raw opium;
(B) Opium extracts;
(C) Opium fluid;
(D) Powdered opium;
(E) Granulated opium;
(F) Tincture of opium;
(G) Codeine;
(H) Dihydroetorphine;
(I) Ethylmorphine;
(J) Etorphine hydrochloride;
(K) Hydrocodone;
(L) Hydromorphone;
(M) Metopon;
(N) Morphine;
(O) Oripavine;
(P) Oxycodone;
(Q) Oxymorphone; and
(R) Thebaine;
(2) Any salt, compound, derivative or preparation thereof
which is chemically equivalent or identical with any of the substances referred
to in subdivision (1) of this subsection, except that these substances shall
not include the isoquinoline alkaloids of opium;
(3) Opium poppy and poppy straw;
(4) Coca leaves and any salt, compound, derivative or
preparation of coca leaves (including cocaine and ecgonine and their salts,
isomers, derivatives and salts of isomers and derivatives), and any salt,
compound, derivative or preparation thereof which is chemically equivalent or
identical with any of these substances, except that the substances shall not
include decocainized coca leaves or extractions of coca leaves, which
extractions do not contain cocaine or ecgonine;
(5) Concentrate of poppy straw (the crude extract of
poppy straw in either liquid, solid or powder form which contains the
phenanthrene alkaloids of the opium poppy).
(c) Opiates. -- Unless specifically excepted or unless in another schedule, any of the following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:
(1) Alfentanil;
(2) Alphaprodine;
(3) Anileridine;
(4) Bezitramide;
(5) Bulk dextropropoxyphene (nondosage forms);
(6) Carfentanil;
(7) Dihydrocodeine;
(8) Diphenoxylate;
(9) Fentanyl;
(10) Isomethadone;
(11) Levo-alphacetylmethadol; some other names:
levo-alpha-acetylmethadol, levomethadyl acetate, LAAM;
(12) Levomethorphan;
(13) Levorphanol;
(14) Metazocine;
(15) Methadone;
(16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,
4-diphenyl butane;
(17) Moramide-Intermediate, 2-methyl-3-morpholino-1,
1-diphenylpropane-carboxylic acid;
(18) Pethidine; (meperidine);
(19) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-
phenylpiperidine;
(20) Pethidine-Intermediate-B,
ethyl-4-phenylpiperidine-4-carboxylate;
(21) Pethidine-Intermediate-C,
1-methyl-4-phenylpiperidine-4-carboxylic acid;
(22) Phenazocine;
(23) Piminodine;
(24) Racemethorphan;
(25) Racemorphan;
(26) Remifentanil;
(27) Sufentanil;
(28) Tapentadol
(29) Thiafentanil
(4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-2-(thienyl)ethylpiperidine),
including its isomers, esters, ethers, salts and salts of isomers, esters and
ethers.
(d) Stimulants. -- Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:
(1) Amphetamine, its salts, optical isomers and salts of
its optical isomers;
(2) Methamphetamine, its salts, isomers and salts of its
isomers;
(3) Methylphenidate;
(4) Phenmetrazine and its salts; and
(5) Lisdexamfetamine.
(e) Depressants. -- Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:
(1) Amobarbital;
(2) Glutethimide;
(3) Pentobarbital;
(4) Phencyclidine;
(5) Secobarbital.
(f) Hallucinogenic substances:
Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] if in an FDA approved oral solution
Nabilone: [Another name for nabilone: (+-)-trans-3-(1, 1-dimethylheptyl)-6, 6a, 7, 8, 10, 10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo [b,d] pyran-9-one].
(g) Immediate precursors. -- Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:
(1) Immediate precursor to amphetamine and
methamphetamine:
(A) Phenylacetone;
(B) Some trade or other names: phenyl-2-propanone; P2P;
benzyl methyl ketone; methyl benzyl ketone;
(2) Immediate precursors to phencyclidine (PCP):
(A) 1-phenylcyclohexylamine; and
(B) 1-piperidinocyclohexanecarbonitrile (PCC).
(3) Immediate precursor to fentanyl:
4-anilino-N-phenethyl-4-piperidine (ANPP).
§60A-2-210. Schedule IV.
(a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.
(b) Narcotic drugs. — Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Not more than 1 milligram of difenoxin and not less
than 25 micrograms of atropine sulfate per dosage unit;
(2)
Dextropropoxyphene
(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane).
(c) Depressants. — Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:
(1) Alprazolam;
(2) Barbital;
(3) Bromazepam;
(4) Camazepam;
(5) Carisoprodol;
(6) Chloral betaine;
(7) Chloral hydrate;
(8) Chlordiazepoxide;
(9) Clobazam;
(10) Clonazepam;
(11) Clorazepate;
(12) Clotiazepam;
(13) Cloxazolam;
(14) Delorazepam;
(15) Diazepam;
(16) Dichloralphenazone;
(17) Estazolam;
(18) Ethchlorvynol;
(19) Ethinamate;
(20) Ethyl loflazepate;
(21) Fludiazepam;
(22) Flunitrazepam;
(23) Flurazepam;
(24) Fospropofol;
(25) Halazepam;
(26) Haloxazolam;
(27) Ketazolam;
(28) Loprazolam;
(29) Lorazepam;
(30) Lormetazepam;
(31) Mebutamate;
(32) Medazepam;
(33) Meprobamate;
(34) Methohexital;
(35) Methylphenobarbital (mephobarbital);
(36) Midazolam;
(37) Nimetazepam;
(38) Nitrazepam;
(39) Nordiazepam;
(40) Oxazepam;
(41) Oxazolam;
(42) Paraldehyde;
(43) Petrichloral;
(44) Phenobarbital;
(45) Pinazepam;
(46) Prazepam;
(47) Quazepam;
(48) Temazepam;
(49) Tetrazepam;
(50) Triazolam;
(51) Zaleplon;
(52) Zolpidem;
(53) Zopiclone’
(54) Suvorexant
([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]
[5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone).
(d) Any material, compound, mixture or preparation which contains any quantity of the following substance, including its salts, isomers (whether optical, position or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible: Fenfluramine and Dexfenfluramine.
(e) Stimulants. — Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:
(1) Cathine ((+)-norpseudoephedrine);
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Mazindol;
(6) Mefenorex;
(7) Modafinil;
(8) Pemoline (including organometallic complexes and
chelates thereof);
(9) Phentermine;
(10) Pipradrol;
(11) Sibutramine;
(12) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
(13) Eluxadoline
(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl
[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid);
(f) Other substances. — Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:
(1) Pentazocine;
(2) Butorphanol.
(3) Tramadol
(2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol);
Amyl nitrite, butyl nitrite, isobutyl nitrite and the other organic nitrites are controlled substances and no product containing these compounds as a significant component shall be possessed, bought or sold other than pursuant to a bona fide prescription or for industrial or manufacturing purposes.
§60A-2-212. Schedule V.
(a) Schedule V shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts.
(b) Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture or preparation containing any of the following narcotic drugs or their salts calculated as the free anhydrous base or alkaloid in limited quantities as set forth below, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone.:
(1) Not more
than 200 milligrams of codeine per 100 milliliters or per 100 grams;
(2) Not more
than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
(3) Not more
than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
(4) Not more
than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
atropine sulfate per dosage unit;
(5) Not more
than 100 milligrams of opium per 100 milliliters or per 100 grams;
(6) Not more
than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine
sulfate per dosage unit.
(c) Stimulants:
— Unless specifically exempted or excluded or unless listed in another
schedule, any material, compound, mixture or preparation which contains any
quantity of the following substances having a stimulant effect on the central
nervous system, including its salts, isomers and salts of isomers:
(1)
Pyrovalerone.
(d) Any compound, mixture or preparation containing as its single active ingredient ephedrine, pseudoephedrine or phenylpropanolamine, their salts or optical isomers, or salts of optical isomers except products which are for pediatric use primarily intended for administration to children under the age of 12: Provided, That neither the offenses set forth in section four hundred one, article four of this chapter, nor the penalties therein, shall be applicable to ephedrine, pseudoephedrine or phenylpropanolamine which shall be subject to the provisions of article ten of this chapter.
(e) Depressants: — Unless specifically exempted
or excluded or unless listed in another schedule, any material, compound,
mixture or preparation which contains any quantity of the following substances
having a depressant effect on the central nervous system, including its salts:
(1)
Ezogabine [N-[2-amino-4-94-fluorobenzylamino)-phenyl]-carbamic acid ethyl
ester];
(2)
Lacosamide [(R)-2-acetoamido- N -benzyl-3-methoxy-propionamide];
(3)
Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]; and
(4)
Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also
referred to as BRV; UCB-34714; Briviact), including its salts.
(f) Other substances:
(1) Gabapentin
(2) Pregabalin
(3) Tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol).
NOTE: The purpose of this bill is to update the schedule of controlled substances.
Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.